Dexamethasone shows survival benefit in severe COVID-19 – how long ago was it?
The background
On June 16, 2020, the British research team from the RECOVERY study reported important progress in the treatment of COVID-19: The drug dexamethasone, which has been available for a long time, reduced the mortality of seriously ill hospital patients in the study. In people on artificial ventilation it fell by around a third, and in patients with additional oxygen by around a fifth. However, there was no benefit for sufferers without respiratory support. It was therefore not only the active ingredient that was crucial, but also the stage of the disease. Dexamethasone dampens inflammatory reactions and was widely available as an inexpensive drug. The initially announced study results provided early evidence that targeted treatment could improve the chances of survival in severe COVID-19. A preventative application could not be derived from this.